Mediators of Inflammation

Research Article

Antiasthmatic Effects of Hesperidin, a Potential Th2 Cytokine Antagonist, in a Mouse Model of Allergic Asthma

Table 1

Quantification by means of FACS analysis of various immune cell subtypes in lung and BALF. Absolute numbers of various immune cell subtypes in lung were counted (described in Section 2). Results are expressed as mean ± S.E ( ). Statistical significance between control and treatment groups was assessed by ANOVA (* , ** , *** ). : Normal BALB/c mice, CT: Ovalbumin inhalation + vehicle, formoterol: OVA + formoterol (1 mg/kg), OVA + HPN (5, 1 mg/kg).
Cell phenotypesNormalOVA-induced asthma mice (Absolute no.)
in lung and BALFBALB/cControlFormoterolHPN (5 mg/kg)HPN (1 mg/kg)
CD3+ (×105 cells)3.43 ± 0.119.47 ± 0.525.08 ± 0.37***3.10 ± 0.59***6.99 ± 0.41**
CD4+ (×105 cells)2.03 ± 0.077.02 ± 0.773.02 ± 0.22**2.51 ± 0.17**5.69 ± 0.79
CD8+ (×105 cells)0.54 ± 0.031.74 ± 0.041.34 ± 0.710.64 ± 0.04***1.53 ± 0.07
Gr-1+/CD11b+ (×105 cells)1.45 ± 0.014.79 ± 0.382.07 ± 0.19**1.25 ± 0.07***2.01 ± 0.27**
CD3−/CCR3+ (×105 cells)Lung0.47 ± 0.094.49 ± 1.012.58±0.221.92 ± 0.13*3.01 ± 0.25
CD3+/CCR3+ (×105 cells)0.17 ± 0.041.74 ± 0.101.19 ± 0.350.91 ± 0.15**1.44 ± 0.04*
CD3+/CD69+ (×105 cells)0.48 ± 0.013.68 ± 0.781.27 ± 0.13*1.42 ± 0.12*2.40 ± 0.82
CD3−/CD19+ (×105 cells)1.08 ± 0.032.89 ± 0.011.66 ± 0.13***1.23 ± 0.21***2.37 ± 0.29
B220+/CD13+ (×105 cells)0.21 ± 0.071.76 ± 0.030.88 ± 0.15**0.42 ± 0.03***0.95 ± 0.26*
CD3+ (×103 cells)0.44 ± 0.1123.94 ± 0.8210.72 ± 0.60**6.88 ±1.55 ** 13.40 ± 4.80
CD4+ (×103 cells)0.43 ± 0.0321.23 ± 1.579.57 ± 0.78**7.92 ± 1.65**15.69 ± 6.08
CD8+ (×103 cells)0.06 ± 0.032.92 ± 0.602.35 ± 0.610.85 ± 0.401.96 ± 0.53
CD3−/CCR3+ (×103 cells)BALF0.03 ± 0.025.75 ± 1.141.62 ± 0.01**0.53 ± 0.11**1.14 ± 0.16**
CD3+/CCR3+ (×103 cells)0.04 ± 0.0110.79 ± 1.155.18 ± 0.44**2.11 ± 0.87**6.34 ± 1.45
B220+/CD23+ (×103 cells)0.12 ± 0.016.64 ± 0.152.65 ± 0.51***0.94 ± 0.32***1.43 ± 0.41***